financetom
Business
financetom
/
Business
/
Petro-Victory Energy to Raise US$2.3 Million Via Private Placement, Provides Corporate Updates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Petro-Victory Energy to Raise US$2.3 Million Via Private Placement, Provides Corporate Updates
Sep 21, 2025 12:28 AM

07:50 AM EDT, 09/19/2025 (MT Newswires) -- Brazil-focused oil and gas company Petro-Victory Energy ( PTVRF ) announced overnight Thursday, that it intends to complete a non-brokered private placement of common shares at C$1.50 each for up to US$2.3 million.

Proceeds will be used for general working capital and capital expenditures related to the development of existing fields. The closing of the offering is anticipated on or about September 26.

In regard to the previously announced binding memorandum of understanding with Azevedo & Travassos Energia (ATE) dated July 2, the company said ATE did not meet the conditions precedent related to the capital raise. Petro-Victory Energy ( PTVRF ) said it is in discussions with ATE to evaluate appropriate modifications for the continuance of the business combination.

On Sept. 3, the 3-AND-5-RN well was completed with a progressing cavity pump, and a production test at the Andorinha Field gathering station is now underway. The company said monitoring will focus on fluid production trends, reservoir pressure response, and water cut stabilization to guide reservoir evaluation and define next development steps.

The company has also extended short-term promissory notes totaling about $4.4 million, now maturing in July 2026. As consideration for the extension, Petro-Victory Energy ( PTVRF ) granted each lender new bonus warrants with like terms effectively extending the original warrants until the new term.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AmEx upgrades Platinum cards with $3,500 annual perks, hikes fee by $200
AmEx upgrades Platinum cards with $3,500 annual perks, hikes fee by $200
Sep 18, 2025
Sept 18 (Reuters) - American Express ( AXP ) unveiled long-awaited upgrades to its U.S. Platinum cards on Thursday, adding new perks worth over $3,500 annually while raising the annual fee by $200. The card refresh reflects a strategy AmEx has leaned on for years. Banking on the affluence of its customer base, the credit card giant routinely adds premium...
Form 8.3 - Alpha Group International PLC
Form 8.3 - Alpha Group International PLC
Sep 18, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Form 8.3 - American Axle & Manufacturing Holdings Inc
Form 8.3 - American Axle & Manufacturing Holdings Inc
Sep 18, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Sep 18, 2025
HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company’s lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic...
Copyright 2023-2026 - www.financetom.com All Rights Reserved